Literature DB >> 34739640

ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma.

Yangxun Pan1,2, Li Xu3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34739640     DOI： 10.1245/s10434-021-11028-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  4 in total

Review 1.  The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review.

Authors:  G K Glantzounis; A Paliouras; M-C Stylianidi; H Milionis; P Tzimas; D Roukos; G Pentheroudakis; E Felekouras
Journal:  Eur J Surg Oncol       Date:  2017-12-12       Impact factor: 4.424

2.  Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

Authors:  MinKe He; QiJiong Li; RuHai Zou; JingXian Shen; WanQiang Fang; GuoSheng Tan; YuanMin Zhou; XiaoPing Wu; Li Xu; Wei Wei; Yong Le; ZhongGuo Zhou; Ming Zhao; Ying Guo; RongPing Guo; MinShan Chen; Ming Shi
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

3.  ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma.

Authors:  Yangxun Pan; Li Xu
Journal:  Ann Surg Oncol       Date:  2021-11-05       Impact factor: 5.344

4.  Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.

Authors:  Ning Lyu; Yanan Kong; Luwen Mu; Youen Lin; Jibin Li; Yaru Liu; Zhenfeng Zhang; Lie Zheng; Haijing Deng; Shaolong Li; Qiankun Xie; Rongping Guo; Ming Shi; Li Xu; Xiuyu Cai; Peihong Wu; Ming Zhao
Journal:  J Hepatol       Date:  2018-02-20       Impact factor: 25.083
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.